Dynavax Technologies Corporation
DVAXDrugs in Pipeline
9
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
Jan 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
HEPLISAV
Hepatitis B
Engerix-B
Hepatitis B
Fendrix
End Stage Renal Disease
HEPLISAV-B
Chronic Kidney Disease
Z-1018
Shingles
Rituxan
Non-Hodgkin's Lymphoma
Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate
Rhinitis, Allergic, Seasonal
rF1V-1018
Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis
rF1V vaccine
Plague, Pneumonic
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HEPLISAV | Phase 3 | Hepatitis B | - | - |
Engerix-B | Phase 3 | Hepatitis B | - | - |
Fendrix | Phase 3 | End Stage Renal Disease | - | - |
HEPLISAV-B | Phase 3 | Chronic Kidney Disease | - | - |
Z-1018 | Phase 2 | Shingles | - | - |
Rituxan | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate | Phase 2 | Rhinitis, Allergic, Seasonal | - | - |
rF1V-1018 | Phase 2 | Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis | - | - |
rF1V vaccine | Phase 2 | Plague, Pneumonic | - | - |
Hepatitis B
2 drugs in this indication
Rhinitis, Allergic, Seasonal
1 drug in this indication
Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis
1 drug in this indication
Plague, Pneumonic
1 drug in this indication
End Stage Renal Disease
1 drug in this indication
Shingles
1 drug in this indication
Chronic Kidney Disease
1 drug in this indication
Healthy
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Dynavax Technologies Corporation's drug pipeline?→
CatalystAlert tracks 9 drug candidates in Dynavax Technologies Corporation's (DVAX) pipeline across Phase 3, Phase 2. Its lead program is HEPLISAV (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Dynavax Technologies Corporation's next FDA catalyst?→
Dynavax Technologies Corporation's (DVAX) next tracked catalyst is a Phase 2 expected January 29, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DVAX biotech catalysts?→
Add DVAX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Dynavax Technologies Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.